A Prospective, Multicenter, Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Tolvaptan in Patients with Reduced, Preserved, and Mid-Range Ejection Fraction Heart Failure-Reference-Cited by-同舟云学术

A Prospective, Multicenter, Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Tolvaptan in Patients with Reduced, Preserved, and Mid-Range Ejection Fraction Heart Failure

Published:2019-09-27 Issue:5 Volume:60 Page:1123-1130
ISSN:1349-2365
Container-title:International Heart Journal
language:en
Short-container-title:Int. Heart J.

Author:

Kinugawa Koichiro¹,Sato Naoki²,Inomata Takayuki³,Yasuda Moriyoshi⁴,Shimakawa Toshiyuki⁴,Fukuta Yasuhiko⁴

Affiliation:

1. Second Department of Internal Medicine, University of Toyama

2. Department of Cardiovascular Medicine, Kawaguchi Cardiovascular and Respiratory Hospital

3. Department of Cardiology, Kitasato University Kitasato Institute Hospital

4. Department of Pharmacovigilance, Otsuka Pharmaceutical Co., Ltd.

Publisher

International Heart Journal (Japanese Heart Journal)

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/ihj/60/5/60_18-671/_pdf

Reference32 articles.

1. 1. Ponikowski P, Anker S, AlHabib K, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail 2014; 1: 4-25.

2. 2. Roger V. Epidemiology of Heart Failure. Circ Res 2013; 113: 646-59.

3. 3. Ziaeian B, Fonarow G. Epidemiology and aetiology of heart failure. Nat Rev Cardiol 2016; 13: 368-78.

4. 4. Savarese G, Lund L. Global Public Health Burden of Heart Failure. Card Fail Rev 2017; 03: 7-11.

5. 5. Wang T, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the Community. Circulation 2003; 108: 977-82.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological and Non-Pharmacological Advancements in Heart Failure Treatment;Reviews in Cardiovascular Medicine;2024-06-25

2. Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape;Heart Failure Reviews;2024-02-27

3. Effectiveness and safety of Tolvaptan in infants with congenital heart disease;Pediatrics International;2023-01

4. The Efficacy and Safety of Short-Term Tolvaptan Usage in Patients with Acute Decompensated Heart Failure;ACTA CARDIOL SIN;2022

5. Heart Failure With Mid-range Ejection Fraction: A Distinctive Subtype or a Transitional Stage?;Frontiers in Cardiovascular Medicine;2021-05-25